Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Lymphadenopathy is not listed in the Summary of Product Characteristics or reported in SURPASS or SURMOUNT clinical trials Common Mounjaro side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and reduced appetite Lymph node swelling during treatment may result from infections, vaccinations, local inflammation, or other unrelated conditions Persistent, enlarging, or hard lymph nodes require GP evaluation to exclude serious underlying causes including malignancy Report any suspected adverse effects through the MHRA Yellow Card Scheme for ongoing pharmacovigilance monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus

For example, if your blood sugar always rises quickly after breakfast, you could do the injection in your abdomen and see whether this improves your blood sugar
Clarifying these pathways may guide preventive or therapeutic strategies and improve patient quality of life
Some patients may also experience dizziness, fatigue, headaches, or mild increases in resting heart rate, particularly those with existing cardiovascular conditions